CHMP says yes to Novartis eye drug but no to its heart treatment, yes to Biogen Idec MS treatment;

@FiercePharma: Takeda now 5 for 6 in winning Actos cases, but that loss was a stunner. Article | Follow @FiercePharma

@TracyStaton: Some AstraZeneca investors are balking at the board's Pfizer snub. Others are practically high-fiving Chairman Johannson. Story | Follow @TracyStaton

@EricPFierce: So you thought you would get through the holidays without more Pfizer/AstraZeneca news? Not a chance. More | Follow @EricPFierce

@CarlyHFierce: Ok, this Rolaids-sponsored spelling bee just passed vaccine car seats for my favorite thing today. Article | Follow @CarlyHFierce

> Europe's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a drug for treating glaucoma from Novartis' ($NVS) Alcon unit. Release

> CHMP recommended against approval of Novartis' heart failure drug serelaxin, a product it hopes could make up for lost sales when generics of blockbuster heart drug Diovan finally hit. Story

> CHMP recommended in favor of approval Biogen Idec's ($BIIB) Plegridy for treating multiple sclerosis. Story

> Janssen Biologics has withdrawn its application in Europe to add an intravenous form of its rheumatoid arthritis drug Simponi after regulators there asked for more data. Report

> Local government officials in Hangzhou, China on Friday said their visit to local offices of Roche ($RHHBY) was routine and unrelated to the anti-bribery investigation that has embroiled GlaxoSmithKline ($GSK) in China. Report

> The FDA asked Internet service providers to close 1,975 websites for selling drugs illegally as part the recent 10-day, international sweep against counterfeit drugs. Release

Medical Device News

@FierceMedDev: Atossa board adopts 'poison pill' remedy in wake of FDA crackdown. More | Follow @FierceMedDev

@VarunSaxena2: After months of silence, FDA returns to name and shame strategy on pediatric trial compliance. Story | Follow @VarunSaxena2

@MichaelGFierce: Smallest, fastest nanomotor moves drugs and releases them on demand. Article | Follow @MichaelGFierce

@EmilyWFierce: Doctors in Italy designed a mini dialysis machine that could save the lives of infants. More | Follow @EmilyWFierce

> iRhythm secures $17 million from VCs for its arrhythmia monitor. News

> Power morcellator fallout continues after FDA advisory warning. More

> J&J: Expect more consolidation in orthopedics industry. Story

Biotech News

@FierceBiotech: This week's EuroBiotech Report: AZ and Europe's 'innovation malaise,' €30M Irish life sci fund, and more. Report | Follow @FierceBiotech

@JohnCFierce: So, something has changed at the CHMP on conditional approvals, and I don't know what it is. Can anyone fill in the blanks here? | Follow @JohnCFierce

@DamianFierce: PTC convinces CHMP to change its mind on conditional approval of the DMD drug ataluren. Story | Follow @DamianFierce

@EmilyMFierce: Beware! Crackpot science: Article. File under: Why I don't watch TV news. | Follow @EmilyMFierce

> Lilly, Boehringer pick up EU nod for FDA-spurned diabetes treatment. More

> The EU's not impressed with Novartis' 'breakthrough' cardio drug, either. Story

> Former CDER official joins Greenleaf Health, biosimilars experience in tow. Chutes & Ladders

And Finally... The wide variety of Type 2 diabetes drugs on the market may be confusing patients and needlessly raising the cost of treatment. Story

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.